Ratings SomnoMed Limited

Equities

SOM

AU000000SOM1

Market Closed - Australian S.E. Other stock markets 11:27:19 26/04/2024 am IST			5-day change	1st Jan Change
0.21 ^AUD	0.00%		-4.55%	-58.00%

10/04	Somnomed Raises AU$5.8 Million in Institutional Entitlement Offer; AU$16.8 Million Retail Component to Launch April 16	MT
09/04	SomnoMed Lowers Earnings, Revenue Guidance for Fiscal 2024; to Launch AU$22.6 Million Entitlement Offer	MT

Summary

The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

The stock, which is currently worth 2024 to 0.33 times its sales, is clearly overvalued in comparison with peers.
The company's share price in relation to its net book value makes it look relatively cheap.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
For the past year, analysts have significantly revised downwards their profit estimates.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
SOMNOMED LIMITED	-58.00%	18.64M	-
ABBOTT LABORATORIES	-2.31%	187B	C+
MEDTRONIC PLC	-3.20%	106B	C
BECTON, DICKINSON AND COMPANY	-5.04%	66.9B	A
DEXCOM, INC.	+0.20%	49.45B	B-
CENCORA, INC.	+17.29%	48B	B-
HOYA CORPORATION	+4.06%	40.84B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+2.07%	26.48B	B
WEST PHARMACEUTICAL SERVICES, INC.	+2.36%	26.25B	A-
TERUMO CORPORATION	+12.96%	24.62B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes